Allen Anderson, MD
Advanced Heart Failure and Transplant Cardiology · San Antonio, TXNPI 1083775811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $301,354 of the $413,390 with a category attached, or 72.9%. 27 manufacturers reported payments, led by Pfizer at 33.4% of the total. Among advanced heart failure and transplant cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $1030.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$138K
- Merck$79K
- Boehringer Ingelheim$65K
- Bayer$39K
- Bridgebio Pharma, Inc.$24K
- Lilly USA, LLC$21K
- plus $49K from 21 others
Across 21 payments — averaging $9581.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$160K
- E.r. Squibb & Sons, L.L.C.$41K
What the payments were for
- Consulting fees$44,65311%
- Speaking & faculty fees$301,35473%
- Travel & lodging$55,56113%
- Food & beverage$11,8223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 126 | $138,210 |
| Merck | 67 | $78,518 |
| Boehringer Ingelheim | 47 | $64,616 |
| Bayer | 26 | $38,605 |
| Bridgebio Pharma, Inc. | 18 | $23,650 |
| Lilly USA, LLC | 17 | $21,214 |
| Novartis | 13 | $14,326 |
| Edwards Lifesciences | 16 | $11,937 |
| GE HealthCare | 2 | $10,400 |
| Vifor Pharma, Inc. | 6 | $6,618 |
| Abiomed | 8 | $963 |
| Abbott | 12 | $961 |
| GSK | 8 | $912 |
| Cvrx, Inc. | 4 | $434 |
| Alnylam Pharmaceuticals Inc. | 14 | $418 |
| E.r. Squibb & Sons, L.L.C. | 3 | $370 |
| Impulse Dynamics (USA) Inc. | 2 | $298 |
| Medtronic | 2 | $225 |
| AstraZeneca | 2 | $168 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $117 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $103 |
| Biotronik Inc. | 1 | $87 |
| Scpharmaceuticals Inc. | 1 | $38 |
| ZOLL Circulation Inc | 1 | $30 |
| Johnson & Johnson | 1 | $27 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$130,681
- VERQUVO$125,630
- JARDIANCE$83,092
- Kerendia$38,403
- Attruby$23,526
- ENTRESTO$14,200
- Veltassa$6,501
- VYNDAMAX$4,293
- Impella$786
- OPTIMIZER$597
- CAMZYOS$370
- Barostim Neo System$342
- HeartWare HVAD$225
- PASCAL$215
- HeartMate 3 Left Ventricular Dev$184
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$155
- Mitra Clip system$149
- EVKEEZA$125
- INSPIRIS RESILIA aortic valve$120
- CARDIOMEMS$119
How this compares
$413,390 in reported general payments places this provider in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 37 | $1,095,903 |
| EntrestoSacubitril/Valsartan | 126 | $197,181 |
| FarxigaDapagliflozin Propanediol | 108 | $151,821 |
| EliquisApixaban | 113 | $131,389 |
| JardianceEmpagliflozin | 82 | $101,513 |
| XareltoRivaroxaban | 13 | $17,189 |
| Bumetanide | 29 | $4,861 |
| VascepaIcosapent Ethyl | 11 | $4,379 |
| Eplerenone | 46 | $2,718 |
| Metoprolol Succinate | 172 | $2,536 |
| Midodrine Hcl | 13 | $1,375 |
| Atorvastatin Calcium | 133 | $1,068 |
| Spironolactone | 166 | $1,044 |
| Rosuvastatin Calcium | 39 | $649 |
| Torsemide | 19 | $526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $138,210 | $1,227,292150 claims |
| NovartisEntresto | $14,326 | $197,181126 claims |
| AstraZenecaFarxiga | $168 | $151,821108 claims |
| Boehringer IngelheimJardiance | $64,616 | $101,51382 claims |
| Johnson & JohnsonXarelto | $27 | $17,18913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in San Antonio
- Alejandro Folch SandovalSan Antonio$44K
- Rashonda CarlisleSan Antonio$30K
- Sachin GuptaSan Antonio$25K
- Mahek ShahSan Antonio$11K
- Tamer AmerSan Antonio$11K
- Mohammed AslamSan Antonio$8K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.